Fig. 9 | Signal Transduction and Targeted Therapy

Fig. 9

From: Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation

Fig. 9

RNA-seq data analysis and validation of MV-4-11 treated with DC551040 or HHT. a Volcano plot showing the degree of gene difference between DC551040-treated group and DMSO control group. b Volcano plot showing the degree of gene difference between HHT-treated group and DMSO control group. c Summary of significantly upregulated pathways after DC551040 treatment based on gene set enrichment analysis (GSEA). d Summary of significantly downregulated pathways after HHT treatment based on gene set enrichment analysis (GSEA). e Based on RNAseq, mRNA counts of IL6 in the DMSO group, DC551040/HHT alone group, and combination group, data are represented as mean ± SEM, n = 3 per group. f Detection of mRNA expression level of MV-4-11 after IL6 knockdown based on qPCR experiment, data are represented as mean ± SEM, n = 3 per group. g Based on the cytotoxicity experiment, the cell viability after treatment with DC551040 was detected under the condition of IL6 knockdown or not, data are represented as mean ± SEM, n = 3 per group. The Significance of (f) was analyzed by equal variance two-tailed t test. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page